Mineralys Therapeutics, Inc.
MLYS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001933414
In the last 90 days, Mineralys Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 225 institutions reported holding it in 13F filings for Q2 2026, worth $2.69B in total; no superinvestor holds it.
Holders of 5% or more of MLYS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Mineralys Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Catalys Pacific Fund, LP | 13G/A | 10.10%8.00M shares | −3.40 ppfrom 13.50% | Feb 13, 20244 filings | Feb 13, 2026 | SEC |
| Ra Capital Management, L.P. | 13D/A | 9.90%7.80M shares | 0.00 ppfrom 9.90% | Feb 24, 20234 filings | Sep 8, 2025 | SEC |
| Samsara BioCapital, L.P. | 13D/A | 8.20%6.35M shares | −0.90 ppfrom 9.10% | Feb 24, 20234 filings | Sep 8, 2025 | SEC |
| BlackRock, Inc. | 13G | 5.20%4.11M shares | New | Jan 21, 20261 filing | Jan 21, 2026 | SEC |
| FMR LLC | 13G/A | 5.10%4.46M shares | −1.20 ppfrom 6.30% | Feb 5, 20262 filings | Aug 6, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
23 Schedule 13D and 13G filings on Mineralys Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 6, 202610:33 AM ET | FMR LLCand 1 other | 13G/A | 5.10%4.46M shares | −1.20 ppfrom 6.30% | Jun 30, 2026 | SEC |
| Feb 13, 20264:30 PM ET | Catalys Pacific Fund, LPand 3 others | 13G/A | 10.10%8.00M shares | −3.40 ppfrom 13.50% | Dec 31, 2025 | SEC |
| Feb 5, 20261:31 PM ET | FMR LLCand 1 other | 13G | 6.30%5.02M shares | New | Dec 31, 2025 | SEC |
| Jan 21, 202612:30 PM ET | BlackRock, Inc. | 13G | 5.20%4.11M shares | New | Dec 31, 2025 | SEC |
| Sep 8, 20258:05 PM ET | Samsara BioCapital, L.P.and 4 others | 13D/A | 8.20%6.35M shares | −0.90 ppfrom 9.10% | Sep 4, 2025 | SEC |
| Sep 8, 20256:00 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 9.90%7.80M shares | 0.00 ppfrom 9.90% | Sep 4, 2025 | SEC |
| Aug 14, 20254:13 PM ET | Andera Partnersand 3 others | 13G/A | 4.20%2.77M shares | –Below 5% | Jun 30, 2025 | SEC |
| Aug 14, 20254:05 PM ET | Catalys Pacific Fund, LPand 3 others | 13G/A | 13.50%8.98M shares | – | Jun 30, 2025 | SEC |
| Mar 17, 20259:06 PM ET | Samsara BioCapital, L.P.and 2 others | 13D/A | 9.10%5.74M shares | – | Mar 13, 2025 | SEC |
| Mar 17, 20257:58 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 9.90%6.29M shares | – | Mar 13, 2025 | SEC |
| Feb 14, 20256:03 AM ET | Adams Street Partners LLCand 7 others | 13G/A | 2.30%1.13M shares | –Below 5% | Dec 31, 2024 | SEC |
| Nov 13, 2024 | TCG Crossover GP II, LLC | 13G/AOld format | – | – | – | SEC |
| Nov 13, 2024 | Catalys Pacific Fund, LP | 13G/AOld format | – | – | – | SEC |
| Nov 13, 2024 | HBM Healthcare Investments (Cayman) Ltd. | 13G/AOld format | – | – | – | SEC |
| Feb 15, 2024 | TCG Crossover GP II, LLC | 13GOld format | – | New | – | SEC |
| Feb 14, 2024 | Adams Street Partners LLC | 13GOld format | – | New | – | SEC |
| Feb 13, 2024 | Catalys Pacific Fund, LP | 13GOld format | – | New | – | SEC |
| Feb 13, 2024 | HBM Healthcare Investments (Cayman) Ltd. | 13GOld format | – | New | – | SEC |
| Feb 12, 2024 | Ra Capital Management, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 12, 2024 | Samsara BioCapital, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 24, 2023 | Andera Partners | 13GOld format | – | New | – | SEC |
| Feb 24, 2023 | Samsara BioCapital, L.P. | 13DOld format | – | New | – | SEC |
| Feb 24, 2023 | Ra Capital Management, L.P. | 13DOld format | – | New | – | SEC |
Form 144: proposed insider sales
94 notices from officers, directors and other affiliates planning to sell Mineralys Therapeutics, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Oct 13, 20264:11 PM ET | Rodman David MalcomOfficer | 3.54K | $78.1K | Oct 13, 202610b5-1 | Merrill Lynch | SEC |
| Sep 30, 20264:07 PM ET | Congleton JonOfficer · Director | 75.0K | $1.91M | Sep 30, 202610b5-1 | Merrill Lynch | SEC |
| Sep 22, 20264:09 PM ET | Catalys Pacific Fund LPDirector | 104.3K | $3.01M | Sep 22, 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Sep 21, 20264:05 PM ET | Warren EricOfficer | 7.44K | $209.1K | Sep 21, 202610b5-1 | Merrill Lynch | SEC |
| Sep 17, 20264:06 PM ET | Rodman David MalcomOfficer | 417 | $11.7K | Sep 17, 202610b5-1 | Merrill Lynch | SEC |
| Sep 15, 20264:19 PM ET | Karydas DaphneOfficer | 3.00K | $85.7K | Sep 15, 202610b5-1 | Merrill Lynch | SEC |
| Sep 14, 20264:06 PM ET | Rodman David MalcomOfficer | 7.71K | $216.9K | Sep 14, 202610b5-1 | Merrill Lynch | SEC |
| Sep 9, 20264:05 PM ET | Rodman David MalcomOfficer | 2.17K | $67.0K | Sep 9, 202610b5-1 | Merrill Lynch | SEC |
| Aug 21, 20264:14 PM ET | Warren EricOfficer | 7.44K | $193.2K | Aug 21, 202610b5-1 | Merrill Lynch | SEC |
| Aug 17, 20264:38 PM ET | Rodman David MalcomOfficer | 417 | $10.6K | Aug 17, 202610b5-1 | Merrill Lynch | SEC |
| Aug 13, 20264:12 PM ET | Rodman David MalcomOfficer | 14.1K | $372.2K | Aug 13, 202610b5-1 | Merrill Lynch | SEC |
| Aug 10, 20264:39 PM ET | Rodman David MalcomOfficer | 2.17K | $58.8K | Aug 10, 202610b5-1 | Merrill Lynch | SEC |
| Jul 21, 20264:11 PM ET | Warren EricOfficer | 7.44K | $199.9K | Jul 21, 202610b5-1 | Merrill Lynch | SEC |
| Jul 17, 20264:03 PM ET | Rodman David MalcomOfficer | 416 | $11.0K | Jul 17, 202610b5-1 | Merrill Lynch | SEC |
| Jul 15, 20264:13 PM ET | Rodman David MalcomOfficer | 6.35K | $169.0K | Jul 15, 202610b5-1 | Merrill Lynch | SEC |
| Jul 14, 202611:08 AM ETAmended | Rodman David MalcomOfficer | 14.1K | $387.7K | Jul 13, 202610b5-1 | Merrill Lynch | SEC |
| Jul 13, 20264:23 PM ET | Congleton JonOfficer · Director | 10.7K | $291.4K | Jul 13, 202610b5-1 | Merrill Lynch | SEC |
| Jul 9, 20264:10 PM ET | Rodman David MalcomOfficer | 2.17K | $65.8K | Jul 9, 202610b5-1 | Merrill Lynch | SEC |
| Jun 30, 20264:20 PM ET | Congleton JonOfficer | 75.0K | $1.96M | Jun 30, 202610b5-1 | Merrill Lynch | SEC |
| Jun 29, 20269:05 AM ET | Warren EricOfficer | 104.1K | $2.70M | Jun 26, 202610b5-1 | Merrill Lynch | SEC |
| Jun 17, 20264:20 PM ET | Rodman David MalcomOfficer | 4.58K | $114.6K | Jun 17, 202610b5-1 | Merrill Lynch | SEC |
| Jun 17, 20264:15 PM ET | Karydas DaphneOfficer | 3.00K | $75.0K | Jun 17, 202610b5-1 | Merrill Lynch | SEC |
| Jun 15, 20264:58 PM ET | Rodman David MalcomOfficer | 9.89K | $235.5K | Jun 15, 202610b5-1 | Merrill Lynch | SEC |
| Jun 12, 20264:17 PM ET | Rodman David MalcomOfficer | 6.35K | $151.9K | Jun 12, 202610b5-1 | Merrill Lynch | SEC |
| Jun 10, 20264:11 PM ET | Rodman David MalcomOfficer | 2.17K | $54.3K | Jun 10, 202610b5-1 | Merrill Lynch | SEC |
Showing the latest 25. See the MLYS notices from the last 12 months